MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas

MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomasMYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas, Published online: 21 May 2018; doi:10.1038/s41379-018-0067-xMYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas
Source: Modern Pathology - Category: Pathology Authors: Source Type: research

Related Links:

Authors: Hotta T, Okimoto T, Hamaguchi M, Tsubata Y, Isobe T Abstract A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with ceritinib as a fifth-line treatment. On day 54 after rechallenge, the patient developed acutely deteriorating dyspnea. Chest computed tomography showed extensive ground-glass opacities. We diagnosed him with ceritinib-induced interstitial lung disease...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
AbstractVenetoclax (Venclyxto®; Venclexta®) is a first-in-class, oral, selective B cell lymphoma-2 (BCL-2) inhibitor. The drug is approved in numerous countries, including those of the EU and in the USA, for the treatment of adults with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL); the specific indication(s) for venetoclax may vary between individual countries. Venetoclax monotherapy or combination therapy with rituximab was an effective treatment, provided durable responses, and had a manageable safety profile in pivotal clinical trials in adults with RR CLL, including in patients with adverse pr...
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 30 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Laura Nanni, Cinzia Pellegrini, Vittorio Stefoni, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We report results of preclinical studies and clinical trials, and discuss the mechanism of action of SINEs and their effects in multiple myeloma, non-Hodgkin lymphomas, lymphoblastic leukemia, and acute and chronic myeloid leukemia. In the future, the numerous experimental studies currently underway will allow us to define the role of SINEs and will possibly permit these substances to be introduced into daily clinical practice.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hyunkyung Park, Ja Min Byun, Youngil Koh, Sung-Soo Yoon, Hyejoo Park, Jayoun Lee, Sang-Jin Shin, Jeonghwan YoukAbstractBackgroundThe optimal the conditioning regimens for allogeneic hematopoietic stem-cell transplantation, especially for East Asian patients, remains unknown.Patients and MethodsWe collected and analyzed clinical and survival data of 4255 patients from the Korean National Health Insurance Claims Database.ResultsBetween 1562 myeloablative conditioning and 2693 nonmyeloablative conditioning groups, the ove...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 19 September 2019Source: Cancer CellAuthor(s): Romain Guièze, Vivian M. Liu, Daniel Rosebrock, Alexis A. Jourdain, María Hernández-Sánchez, Aina Martinez Zurita, Jing Sun, Elisa Ten Hacken, Kaitlyn Baranowski, Philip A. Thompson, Jin-Mi Heo, Zachary Cartun, Ozan Aygün, J. Bryan Iorgulescu, Wandi Zhang, Giulia Notarangelo, Dimitri Livitz, Shuqiang Li, Matthew S. Davids, Anat BiranSummaryMitochondrial apoptosis can be effectively targeted in lymphoid malignancies with the FDA-approved B cell lymphoma 2 (BCL-2) inhibitor venetoclax, but resistance to thi...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Conditions:   Follicular Lymphoma (Gastric or Duodenal);   Marginal Zone Lymphoma (Gastric or Duodenal) Intervention:   Radiation: Radiation Therapy Sponsors:   University Hospital Muenster;   International Lymphoma Radiation Oncology Group (ILROG) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Nasal Type Extranodal NK/T-Cell Lymphoma Interventions:   Drug: Pegaspargase;   Drug: Anti-PD-1 monoclonal antibody Sponsor:   Ruijin Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: Expression of a constitutively activated ALK mutant in thyroids of mice leads to development of metastasizing thyroid cancer resembling human PDTC. These results demonstrate in vivo that increased ALK activity is a driver mechanism in thyroid carcinogenesis. PMID: 31526103 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
Authors: Ying Z, Shiue L, Park K, Kollet J, Bijani P, Goswami M, Duvic M, Ni X Abstract [This corrects the article DOI: 10.18632/oncotarget.26900.]. PMID: 31534633 [PubMed - in process]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Lymphoma | Pathology | Study